Publication:
Management of Systemic Hypersensitivity Reactions to Gonadotropin-Releasing Hormone Analogues during Treatment of Central Precocious Puberty

dc.contributor.authorBEREKET, ABDULLAH
dc.contributor.authorÖZEN, AHMET OĞUZHAN
dc.contributor.authorBARIŞ, SAFA
dc.contributor.authorDEMİRCİOĞLU, SERAP
dc.contributor.authorGÜRAN, TÜLAY
dc.contributor.authorsKirkgoz, Tarik; Karakoc-Aydiner, Elif; Bugrul, Fuat; Abali, Zehra Yavas; Helvacioglu, Didem; Kiykim, Ayca; Eltan, Sevgi Bilgic; Kasap, Nurhan Aruci; Baris, Safa; Ozen, Ahmet; Guran, Tulay; Bereket, Abdullah; Turan, Serap
dc.date.accessioned2022-03-12T22:44:31Z
dc.date.accessioned2026-01-11T10:24:43Z
dc.date.available2022-03-12T22:44:31Z
dc.date.issued2020
dc.description.abstractBackground:Besides local reactions, systemic hypersensitivity reactions such as urticaria, anaphylaxis, serum sickness and Henoch-Schonlein purpura (HSP) have been reported during gonadotropin-releasing hormone (GnRH) analogue treatment.Aim:To present the clinical presentation of 9 cases with systemic hypersensitivity reactions to GnRH analogues and discuss the management of such reactions based on our experience.Patients and Methods:Nine of 232 (3.8%) patients with central precocious puberty receiving GnRH analogue treatment had systemic hypersensitivity reactions in 4 years' period. Six patients had a type 1 hypersensitivity reaction (generalized hives, pruritus, and/or edema) to triptorelin acetate (TA), 2 patients to leuprolide acetate (LA), and 1 patient to both medications who also developed anaphylaxis to LA during intradermal test (IDT). Another patient on TA had skin lesions suggestive of HSP. GnRH analogue treatment was discontinued in 2 patients after discussion with the parents. Treatment was changed to another GnRH analogue preparation in 6 patients and was maintained with the same medication with antihistamines and corticosteroid premedication in 1 patient. None of the patients developed new reactions after these precautions.Conclusion:Systemic hypersensitivity reactions should be carefully evaluated and cross-reaction to the other GnRH analogues should be kept in mind. Discontinuation of GnRH analogue is always an option. However, if continuation of GnRH analogue is elected, we recommend switching to an alternative GnRH analogue, which should be considered only after a skin prick test (SPT) and IDT. In the lack of the possibility to perform SPT and IDT, injections may be administered under strict medical supervision in a well-equipped facility to manage anaphylaxis. We discuss additional options in situations where alternative GnRH analogues are unavailable, which enabled us to continue treatment in most cases without further problems.
dc.identifier.doi10.1159/000505329
dc.identifier.eissn1663-2826
dc.identifier.issn1663-2818
dc.identifier.pubmed31972562
dc.identifier.urihttps://hdl.handle.net/11424/236438
dc.identifier.wosWOS:000546456300008
dc.language.isoeng
dc.publisherKARGER
dc.relation.ispartofHORMONE RESEARCH IN PAEDIATRICS
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectAdverse reactions
dc.subjectAnaphylaxis
dc.subjectCentral precocious puberty
dc.subjectDrug-related side effects
dc.subjectGonadotropin-releasing hormone analogues
dc.subjectLEUPROLIDE ACETATE
dc.subjectRECURRENT ANAPHYLAXIS
dc.subjectTRIPTORELIN
dc.titleManagement of Systemic Hypersensitivity Reactions to Gonadotropin-Releasing Hormone Analogues during Treatment of Central Precocious Puberty
dc.typearticle
dspace.entity.typePublication
oaire.citation.endPage72
oaire.citation.issue1
oaire.citation.startPage66
oaire.citation.titleHORMONE RESEARCH IN PAEDIATRICS
oaire.citation.volume93

Files